Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.51 |
| ▸ | ACHE | P22303 | 1/20 | 0.51 |
| ▸ | CNR2 | P34972 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.41 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.41 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.39 |
| ▸ | RELA | Q04206 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5431708 | 0.81 | CNR2 (0.56) | CNR1ACHECNR2PTGER4MAPT | |
| SCHEMBL5297088 | 0.79 | CNR1 (0.49) | CNR1ACHECNR2SMN1; SMN2MAPT | |
| SCHEMBL4028459 | 0.75 | CNR1 (0.49) | CNR1ACHECNR2L3MBTL1SLC2A1 | |
| SCHEMBL960723 | 0.74 | SMN1; SMN2 (0.44) | CNR1ACHECNR2L3MBTL1PTGER4 | |
| SCHEMBL215702 | 0.74 | EGFR (0.53) | EGFR | |
| SCHEMBL30729935 | 0.74 | EGFR (0.53) | EGFR | |
| SCHEMBL5433673 | 0.73 | ALDH1A1 (0.44) | L3MBTL1EGFRPTGER4SMN1; SMN2MAPT | |
| Hydrochloric Acid SCHEMBL1353996 | 0.73 | EGFR (0.52) | EGFR | |
| SCHEMBL5443607 | 0.71 | KDM4C (0.39) | CNR1ACHECNR2GRM2KMT2A | |
| SCHEMBL3322212 | 0.71 | CNR1 (0.64) | CNR1ACHECNR2L3MBTL1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101098857-A | Nitro indazole derivatives | ASTRAZENECA AB (SE) | 2008-01-02 | — | — | CN | disclosed |
| US-20070265325-A1 | Nitro Indazole Derivatives | ASTRAZENECA AB (SE) | 2007-11-15 | — | — | US | disclosed |
| US-20070265325-A1 | Nitro Indazole Derivatives | ASTRAZENECA AB (SE) | 2007-11-15 | — | — | US | disclosed |
| US-20070265325-A1 | Nitro Indazole Derivatives | ASTRAZENECA AB (SE) | 2007-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265325-A1 | Nitro Indazole Derivatives | NOS3, CYP3A43, NOS2 | CNR1 155/4885ACHE 58/4885CNR2 210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.